Tengion — Investor Presentation (January 2013)
26 slides from Tengion's investor presentation, Jan 7, 2013
Slide 1: Regenerative medicine brought to life
s ® tengien Regenerative medicine brought to life. January 2013
Slide 2: Forward-Looking Statements
* Forward-Looking Statements Certain statements in this presentation may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Although Tengion believes that these statements are based upon reasonable assumptions within the bounds of its kn
Slide 3: Investment Highlights
* Investment Highlights Biotechnology company with unique technology platform for tissue and organ regeneration using a patient’s own cells Neo-Urinary Conduit™: Improve upon standard of care for bladder cancer patients requiring cystectomy Complete patient implants in 1Q 2013 for ongoing Phase 1 tr
Slide 4: Delivering Organ Regeneration for Patients
* Delivering Organ Regeneration for Patients
Slide 5: Neo-Urinary Conduit
* Neo-Urinary Conduit
Slide 6: Neo-Urinary Conduit: Large Market Opportunity
* Neo-Urinary Conduit: Large Market Opportunity Estimated Urinary Diversion Surgical Procedures in 2012 * 13,100 15,200 *L.E.K. and company estimates Number of procedures growing at ~3% per annum
Slide 7: Standard-of-Care for Urinary Diversion
* Standard-of-Care for Urinary Diversion Standard-of-Care Long surgical time (4–6 hours) Extended recovery time (weeks – months) Use of bowel creates absorption challenges and can lead to metabolic disorders
Slide 8: Advantages of Neo-Urinary Conduit
* Advantages of Neo-Urinary Conduit Neo-Urinary Conduit Advantages: Surgery shorter and less complex Improved recovery times and faster hospital discharges No evidence of typical post-operative co-morbidities found with current standard of care
Slide 9: Neo-Urinary Conduit: Potential to Establish New Standard of Care for Cystectomy
* Neo-Urinary Conduit: Potential to Establish New Standard of Care for Cystectomy Designed to establish new standard of care for bladder cancer patients undergoing cystectomy (removal of bladder) Eliminates need for bowel resection and urine absorption-related metabolic disorders 70% of patients rec
Slide 10: Neo-Urinary Conduit Phase 1 Clinical Trial
* Neo-Urinary Conduit Phase 1 Clinical Trial
Slide 11: Neo-Urinary Conduit Phase 1 Trial Progress
* Neo-Urinary Conduit Phase 1 Trial Progress: Defining Translation and Regeneration Insights gained from 6 patients implanted to date: Surgical procedure for a NUC implantation activates urinary tissue regeneration in patients with bladder cancer Initial post-operative care for patency and durabilit
Slide 12: Positive Initial Payer Comments
* Positive Initial Payer Comments Payers believe a $40,000 price for Neo-Urinary Conduit is reasonable Incremental cost savings Reduction in surgery and hospitalization time Reduction in complications Quality of life improvements Limited incremental exposure per payer Older population likely covered
Slide 13: Neo-Kidney Augment
* Neo-Kidney Augment
Slide 14: Neo-Kidney Augment: Robust Clinical Program
* Neo-Kidney Augment: Robust Clinical Program Intended to prevent or delay dialysis and transplantation by increasing renal function in patients with advanced CKD Catalyze regeneration of functional renal tissue using a patient’s own kidney cells Robust preclinical data for neo-kidney augment with d
Slide 15: Neo-Kidney Augment: Significant Market Opportunity
* Neo-Kidney Augment: Significant Market Opportunity
Slide 16: Neo-Kidney Augment: Strong Body of Preclinical Data to Support IND Filing
* Neo-Kidney Augment: Strong Body of Preclinical Data to Support IND Filing Significant effects in aggressive rodent models of diabetic kidney failure and CKD – results published in top-tier journals Diabetic kidney failure model Uncontrolled diabetic, obese, hypertensive rodent model of kidney fail
Slide 17: Efficient and Scalable Manufacturing Process
* Efficient and Scalable Manufacturing Process
Slide 18: Multiple Mechanisms of Action in CKD
* Multiple Mechanisms of Action in CKD Implanted regenerative cells persist for at least 6 months Regeneration of functional renal tissue Regenerative and resident cells regenerate, replace and repair renal structures post-implantation Attenuation of inflammatory and fibrosis pathways Molecular evid
Slide 19: Neo-Kidney Augment: Near-Term Initiatives in Europe
* Neo-Kidney Augment: Near-Term Initiatives in Europe
Slide 20: Neo-Kidney Augment: Near-Term Initiatives in U.S.
* Neo-Kidney Augment: Near-Term Initiatives in U.S.
Slide 21: Corporate
* Corporate
Slide 22: Significant IP and Barriers to Entry
* Significant IP and Barriers to Entry Technology protected by issued patent protection plus recent applications pending 28 U.S. and 97 international patents and patent applications for regeneration of multiple organs and tissues Core patents cover composition, design and methods of manufacture* Two
Slide 23: Financial Overview
* Financial Overview September 30, 2012 Cash and investments Long-term debt Adjusted net loss Shares outstanding * $1.4 M $4.5 M $13.0 M 2.5 M December 31, 2011 $15.3 M $5.0 M $19.1 M 2.4 M * Shares outstanding for all periods have been adjusted to reflect the reverse stock split of one-for-ten effe
Slide 24: Upcoming Clinical Milestones
* Upcoming Clinical Milestones Milestone Expected Neo-Urinary Conduit Complete enrollment of Phase 1 clinical trial 1Q 13 Obtain 1-year data from Phase 1 clinical trial 1Q 14 Neo-Kidney Augment CTA filing in Sweden 1Q 13 IND filing in U.S. 2Q 13 Start Phase 1 clinical trials in CKD patients Sweden U
Slide 25: Investment Highlights
* Investment Highlights Biotechnology company with unique technology platform for tissue and organ regeneration using a patient’s own cells Neo-Urinary Conduit™: Improve upon standard of care for bladder cancer patients requiring cystectomy Complete patient implants in 1Q 2013 for ongoing Phase 1 tr
Slide 26: Regenerative medicine brought to life
s ® tengien Regenerative medicine brought to life. January 2013